Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia (EDELIFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04980638
Recruitment Status : Recruiting
First Posted : July 28, 2021
Last Update Posted : May 6, 2023
Pierre Fabre Medicament
Iqvia Pty Ltd
Information provided by (Responsible Party):
EspeRare Foundation

Brief Summary:
This is an open-label, prospective, genotype-match controlled for primary estimand, non randomized, multicenter, international Phase 2 clinical trial designed to investigate the efficacy and safety of ER004 administered intraamniotically as a treatment for unborn XLHED male subjects.

Condition or disease Intervention/treatment Phase
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Biological: ER004 Phase 2

Detailed Description:
X-linked hypohidrotic ectodermal dysplasia (XLHED) is a rare developmental disease affecting body parts derived from the embryonal ectoderm. It is caused by a broad spectrum of mutations in the ectodysplasin A gene (EDA). The main symptoms of XLHED are hypo- or anhidrosis, oligo- or anodontia, and hypotrichosis. Current treatment options are limited to the management of disease symptoms and prevention of complications. Effective corrective treatment for XLHED remains a high unmet medical need. ER004 represents a first-in-class signaling protein replacement molecule designed for specific, high affinity binding to the endogenous EDA1 receptor (EDAR). The proposed mechanism of action of ER004 is the replacement of the missing EDA1 protein in patients with XLHED. The aim of this prospective, open-label, genotype-match controlled, multicenter Phase 2 trial is to confirm the efficacy and safety results for ER004 administered intra-amniotically in a larger cohort of subjects. The target population will consist of male XLHED fetuses/subjects with EDA mutation confirmed by genetic diagnosis of a mutation in one of the maternal EDA alleles and ultrasonographic diagnosis of a significantly reduced number of fetal tooth germs, or by documented direct genetic diagnosis of a hemizygous EDA mutation. In the main study phase, efficacy and safety of the treated subjects will be assessed up to 6 months of age and safety of the mothers will be assessed up to 1 month after delivery of the child. In long-term follow-up phase, efficacy and safety of the treated subjects will be assessed up to 5 years of age. Treated subjects sweating ability will be compared to an untreated relative from his family, when available, or from a matched controlled subject from a previous natural history.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is an open-label, single-arm, genotype-match controlled for primary estimand, non randomized study. The primary efficacy outcome will be compared to genotype matched untreated male relatives with XLHED or to genotype-matched controls from an external XLHED database (clinical and natural history studies from which untreated genotype-matched controls will be identified).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-label, Genotype-match Controlled, Multicenter Clinical Trial to Investigate the Efficacy and Safety of Intra-amniotic ER004 as a Prenatal Treatment for Male Subjects With XLHED
Actual Study Start Date : April 26, 2022
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : January 2029

Arm Intervention/treatment
Experimental: ER004
Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor binding domain fusion protein.
Biological: ER004
Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26

Primary Outcome Measures :
  1. Mean sweat volume [ Time Frame: at 6 months of age (corrected age for subjects born at < 37 weeks) ]
    For treated subject, mean sweat volume is collected on both forearms after local stimulation with pilocarpine (pilocarpine-induced sweating)

Secondary Outcome Measures :
  1. Mean sweat pore density (number/cm2) [ Time Frame: at 6 months of age (key secondary) and other timepoints : 3, 12, 18, 24, 36, 48 and 60 months of age (secondary) ]
    Mean sweat pore density (number/cm2) determined by direct visualization with a VivaScope® at 2 different sites on the sole/soles of the foot/feet (up to 12 months) or at 2 different sites on the sole/soles of the foot/feet and/or palm/palms of the hand/hands (>12 months)

  2. Dental development [ Time Frame: at 6 months of age (key secondary) and other timepoints : 12, 18, 24, 36, 48 and 60 months of age (secondary) ]
    Dental development evaluated by the number of erupted teeth and tooth germs (palpable alveolar structures in the alveolar ridge) as determined by dental examination

  3. Mean sweat volume [ Time Frame: At 3, 12, 18, 24, 36, 48, 60 months of age ]
    For treated subject, mean sweat volume is collected on both forearms after local stimulation with pilocarpine (pilocarpine-induced sweating)

  4. Number of Meibomian glands [ Time Frame: At 6 and 60 months of age ]
    Number of Meibomian glands in the lower eyelids determined by Meibography

  5. Ocular surface assessment [ Time Frame: At 24, 48 and 60 months of age ]
    Ocular surface assessment (normal, keratitis superficialis punctate) by eye using fluorescein

  6. Tear film break-up time [ Time Frame: At 24, 48 and 60 months of age ]
    Tear film break-up time (seconds) determined using fluorescein

  7. Ocular Surface Disease Index (OSDI) score [ Time Frame: At 60 months of age ]
    Score assessed on a scale of 0 to 100 through the OSDI questionnaire. Higher scores mean a worse outcome

  8. Salivation [ Time Frame: At 60 months of age ]
    Saliva (volume and flow rate) assessed with Quantisal oral fluid collection device

  9. XLHED-related hospitalizations [ Time Frame: Up to 60 months of age ]
    XLHED-related hospitalisation because of hyperthermia or because of unexplained fever, respiratory, skin, eye or ear infections

  10. Assessment of eczema [ Time Frame: At different timepoints from 6 to 60 months of age ]
    Eczema will be assessed using the EASI score

  11. Incidence of TEAEs (treatment-emergent adverse events) [ Time Frame: Up to 60 months of age ]
    Number of subjets with TEAEs

  12. Incidence of TESAEs (treatment-emergent serious adverse events) [ Time Frame: Up to 60 months of age ]
    Number of subjects with TESAEs

  13. Incidence of TEAEs (treatment-emergent adverse events) leading to treatment discontinuation [ Time Frame: Up to 60 months of age ]
    Number of subjects with TEAEs leading to treatment discontinuation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Pregnant female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

For mother: adult mother with confirmed pregnancy no later than week 23+6 and genetically confirmed as carrier of an EDA mutation

  • For fetal subject : male fetal subject with confirmed diagnosis of XLHED
  • For untreated relative: untreated male relative subject aged between 6 months and 75 years with the same EDA mutation as the treated subject

Exclusion Criteria:

  • For mother: any evidence of active maternal infection associated with a risk of preterm birth and/or congenital anomalies of prenatal and postnatal risk to the child. Documented maternal HIV infection. Any pre-existing maternal medical condition that increases the risk of preterm birth or increases the risk of a serious untoward event occurring to the mother during pregnancy. Any pregnancy disorder associated with an increased risk of preterm birth, and/or maternal, fetal or neonatal morbidity/mortality.
  • For fetal subject : second major anatomic anomaly (not related to the underlying XLHED) that contributes to a significant morbidity or mortality risk, or echocardiogram or ultrasonography or other findings that indicate a high risk of fetal demise or risk of preterm birth. Any condition other than XLHED that is likely to have an impact on the number of tooth germs. Any other medical condition which in the opinion of the investigator would not allow for safe conduct of the study for the subject, or that would interfere with efficacy assessments.
  • For untreated relative: carrier of an hypomorphic EDA mutation. Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists. Presence of an implanted device (e.g., defibrillator, neurostimulator, pacemaker). Previous treatment with the study intervention by any route of administration prior to study start.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04980638

Layout table for location contacts
Contact: Florence Porte-Thormé, PharmD +41 22 794 4004
Contact: Athmane Bouroubi, MD +33 5 34 50 60 00

Layout table for location information
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Dorothy Grange   
Hôpital Necker - Enfants Malades Recruiting
Paris Cedex 15, Paris, France, 75743
Contact: Christine Bodemer   
Universitaetsklinikum Erlangen Recruiting
Erlangen, Bayern, Germany, 91054
Contact: Holm Schneider   
Universitaetsklinikum Leipzig AoeR Recruiting
Leipzig, Sachsen, Germany, 04103
Contact: Holger Stepan   
IRCCS Ca' Granda Ospedale Policlinico Recruiting
Milan, Italy, 20122
Contact: Riccardo Cavalli   
Hospital Universitario Virgen de la Arrixaca Recruiting
El Palmar, Murcia, Spain, 30120
Contact: Encarnacion Guillen Navarro   
United Kingdom
University Hospital of Wales Cardiff and Vale University Local Health Recruiting
Cardiff, United Kingdom, CF14 4XW
Contact: Angus Clarke   
Sponsors and Collaborators
EspeRare Foundation
Pierre Fabre Medicament
Iqvia Pty Ltd
Layout table for investigator information
Principal Investigator: Holm Schneider, MD University Erlangen-Nürnberg Erlangen, Germany
Additional Information:
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: EspeRare Foundation Identifier: NCT04980638    
Other Study ID Numbers: ER004-CLIN01/F60082AI201
First Posted: July 28, 2021    Key Record Dates
Last Update Posted: May 6, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ectodermal Dysplasia
Ectodermal Dysplasia 1, Anhidrotic
Abnormalities, Multiple
Congenital Abnormalities
Skin Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Genetic Diseases, X-Linked